Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/198662
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lleixà, Cinta | - |
dc.contributor.author | Caballero Ávila, Marta | - |
dc.contributor.author | Pascual Goñi, Elba | - |
dc.contributor.author | Martín Aguilar, Lorena | - |
dc.contributor.author | Vidal, Nuria | - |
dc.contributor.author | Tejada, Clara | - |
dc.contributor.author | Valdés Hevia, Eduardo | - |
dc.contributor.author | Zárate, Elisa | - |
dc.contributor.author | Vesperinas, Ana | - |
dc.contributor.author | Collet, Roger | - |
dc.contributor.author | Franco Leyva, Teresa | - |
dc.contributor.author | Martínez Martínez, Laura | - |
dc.contributor.author | Moga, Esther | - |
dc.contributor.author | Cortés Vicente, Elena | - |
dc.contributor.author | Rojas García, Ricard | - |
dc.contributor.author | Gómez Anson, Beatriz | - |
dc.contributor.author | Gil, Anna | - |
dc.contributor.author | González Mingot, Cristina | - |
dc.contributor.author | Brieva, Luis | - |
dc.contributor.author | Martínez Yélamos, Sergio | - |
dc.contributor.author | Querol, Luis | - |
dc.date.accessioned | 2023-05-30T07:49:21Z | - |
dc.date.available | 2023-05-30T07:49:21Z | - |
dc.date.issued | 2023-03-02 | - |
dc.identifier.issn | 2632-1297 | - |
dc.identifier.uri | http://hdl.handle.net/2445/198662 | - |
dc.description.abstract | Lleixa and Caballero-avila et al. report that antibodies targeting the flotillin-1/2 complex are present in a subgroup of patients with multiple sclerosis. Further studies are needed to understand the clinical and pathological relevance of anti-flotillin-1/2 autoantibodies in multiple sclerosis. Multiple sclerosis is a tissue-specific autoimmune disease of the central nervous system in which the antigen(s) remains elusive. Antibodies targeting the flotillin-1/2 complex have been described in 1-2% of the patients in a recent study. Other candidate antigens as anoctamin-2 or neurofascin-155 have been previously described in multiple sclerosis patients, although their clinical relevance remains uncertain. Our study aims to analyse the frequency and clinical relevance of antibodies against neurofascin-155, anoctamin-2 and flotillin-1/2 complex in multiple sclerosis. Serum (n = 252) and CSF (n = 50) samples from 282 multiple sclerosis patients were included in the study. The control group was composed of 260 serum samples (71 healthy donors and 189 with other neuroinflammatory disorders). Anti-flotillin-1/2, anti-anoctamin-2 and anti-neurofascin-155 antibodies were tested by cell-based assays using transfected cells. We identified six multiple sclerosis patients with antibodies against the flotillin-1/2 complex (2.1%) and one multiple sclerosis patient with antibodies against anoctamin-2 (0.35%). All multiple sclerosis patients were negative for anti-neurofascin-155 antibodies. Three of the anti-flotillin-1/2 positive patients showed anti-flotillin-1/2 positivity in other serum samples extracted at different moments of their disease. Immunoglobulin G subclasses of anti-flotillin-1/2 antibodies were predominantly one and three. We confirm that antibodies targeting the flotillin-1/2 complex are present in a subgroup of patients with multiple sclerosis. Further studies are needed to understand the clinical and pathological relevance of anti-flotillin-1/2 autoantibodies in multiple sclerosis. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Oxford University Press (OUP) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1093/braincomms/fcad109 | - |
dc.relation.ispartof | Brain Communications, 2023, vol. 5, num. 2 | - |
dc.relation.uri | https://doi.org/10.1093/braincomms/fcad109 | - |
dc.rights | cc by (c) Lleixà, Cinta et al, 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Esclerosi múltiple | - |
dc.subject.classification | Antígens | - |
dc.subject.other | Multiple sclerosis | - |
dc.subject.other | Antigens | - |
dc.title | Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-05-22T08:19:11Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37091585 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fcad109.pdf | 1.14 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License